Until recently, the UN was on track to meet its target of ending AIDS as a public health threat by 2030. But with the U.S.

(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

A pivotal moment in the fight to end AIDS -- ensuring lifesaving innovation reaches those who need it most, wherever they liveThe Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) ...

Only 17,000 Ugandans to benefit from $1.1m Global Fund support as officials warn of high demand for long-acting prevention ...

Devastating funding cuts from international donors are hitting countries hardest affected by HIV — but many are showing ...

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Global Fund notes that the US has contributed more than $26.31 billion to date and pledged up to $6 billion for the Seventh ...

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

Gilead Sciences, in partnership with the Global Fund, plans to supply a long-acting HIV prevention drug to low-income ...

DAR ES SALAAM: TANZANIA National Coordinating Mechanism (TNCM) has reaffirmed its commitment to ensure the Global Fund ...